AR091770A1 - Indolcarbonitrilos moduladores selectivos de receptores androgenicos - Google Patents

Indolcarbonitrilos moduladores selectivos de receptores androgenicos

Info

Publication number
AR091770A1
AR091770A1 ARP130102513A ARP130102513A AR091770A1 AR 091770 A1 AR091770 A1 AR 091770A1 AR P130102513 A ARP130102513 A AR P130102513A AR P130102513 A ARP130102513 A AR P130102513A AR 091770 A1 AR091770 A1 AR 091770A1
Authority
AR
Argentina
Prior art keywords
indolcarbonitrils
selective modulators
androgenic receptors
androgenic
receptors
Prior art date
Application number
ARP130102513A
Other languages
English (en)
Original Assignee
Glaxosmithkline Intellectual Property N 2 Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49117887&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR091770(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxosmithkline Intellectual Property N 2 Ltd filed Critical Glaxosmithkline Intellectual Property N 2 Ltd
Publication of AR091770A1 publication Critical patent/AR091770A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/24—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an alkyl or cycloalkyl radical attached to the ring nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06—Anabolic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)

Abstract

Reivindicación 1: Un compuesto de acuerdo con la fórmula (1) o una sal del mismo, en donde: ⁻ ⁻ ⁻ ⁻ ⁻ indica un enlace individual o doble; R¹ es -CF₃, -CºN, o halógeno; R² es H, alquilo C₁₋₃, o -CHF₂; R³ es alquilo C₁₋₃; R⁴ es -C(CH₃)-(CF₃)OH, -CH₂SCH₃, -CH₂S(O)₂CH₃, -C(O)CH₃, o fenilo o piridinilo, en donde el fenilo o piridinilo está opcionalmente sustituido con uno o dos grupos seleccionados a partir de -CºN y halógeno; y R⁵ es H o metilo.
ARP130102513A 2012-07-17 2013-07-15 Indolcarbonitrilos moduladores selectivos de receptores androgenicos AR091770A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261672455P 2012-07-17 2012-07-17
US201361748874P 2013-01-04 2013-01-04

Publications (1)

Publication Number Publication Date
AR091770A1 true AR091770A1 (es) 2015-02-25

Family

ID=49117887

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP130102513A AR091770A1 (es) 2012-07-17 2013-07-15 Indolcarbonitrilos moduladores selectivos de receptores androgenicos

Country Status (39)

Country Link
US (5) US8957104B2 (es)
EP (1) EP2875013B1 (es)
JP (1) JP6106746B2 (es)
KR (1) KR102127939B1 (es)
CN (1) CN104619693B (es)
AR (1) AR091770A1 (es)
AU (1) AU2013291721B2 (es)
BR (1) BR112015000940B1 (es)
CA (1) CA2879104C (es)
CL (1) CL2015000119A1 (es)
CO (1) CO7240378A2 (es)
CR (1) CR20150008A (es)
CY (1) CY1120064T1 (es)
DK (1) DK2875013T3 (es)
DO (1) DOP2015000004A (es)
EA (1) EA026371B8 (es)
ES (1) ES2657912T3 (es)
HK (1) HK1208867A1 (es)
HR (1) HRP20180061T1 (es)
HU (1) HUE036238T2 (es)
IL (1) IL236448A (es)
IN (1) IN2014KN02993A (es)
JO (1) JO3384B1 (es)
LT (1) LT2875013T (es)
ME (1) ME02996B (es)
MX (1) MX349943B (es)
MY (2) MY198512A (es)
NZ (1) NZ703129A (es)
PE (1) PE20150371A1 (es)
PH (1) PH12015500104A1 (es)
PL (1) PL2875013T3 (es)
PT (1) PT2875013T (es)
RS (1) RS56810B1 (es)
SG (1) SG11201408493WA (es)
SI (1) SI2875013T1 (es)
TW (1) TWI574946B (es)
UY (1) UY34911A (es)
WO (1) WO2014013309A1 (es)
ZA (1) ZA201500096B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10155099B2 (en) 2009-09-21 2018-12-18 Cook Regentec Llc Method for infusing stem cells
AU2013291721B2 (en) 2012-07-17 2016-02-25 Glaxosmithkline Intellectual Property (No.2) Limited Indolecarbonitriles as selective androgen receptor modulators
WO2015110958A1 (en) * 2014-01-21 2015-07-30 Glaxosmithkline Intellectual Property (No.2) Limited Crystalline forms of (r)-1 -(1-(methylsulfonyl)propan-2-yl)-4-(trifluoromethyl)indoline-5-carbonitrile
KR101994922B1 (ko) * 2014-10-16 2019-07-01 지티엑스, 인코포레이티드 Sarm을 이용하는 비뇨기 장애의 치료 방법
CN105130872B (zh) * 2015-08-25 2018-01-30 江西师范大学 一种3位三氟甲基取代吲哚的制备方法
CN110437125B (zh) * 2019-09-06 2021-03-12 苏州旺山旺水生物医药有限公司 一种Tezacaftor中间体II的制备方法
US20220306609A1 (en) * 2021-03-23 2022-09-29 Nido Biosciences, Inc. Bicyclic compounds as androgen receptor modulators
CN115010574B (zh) * 2022-06-06 2024-01-05 爱斯特（成都）生物制药股份有限公司 1-溴-2-氯-4-氟-2碘苯的合成方法

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2322161A1 (en) 1998-02-25 1999-09-02 Yibin Xiang Inhibitors of phospholipase enzymes
IL139586A0 (en) * 1998-06-19 2002-02-10 Pfizer Prod Inc PYRROLO [2,3-d] PYRIMIDINE COMPOUNDS
US6576265B1 (en) 1999-12-22 2003-06-10 Acell, Inc. Tissue regenerative composition, method of making, and method of use thereof
EP1511724B1 (en) 2002-05-24 2014-04-30 Bayer CropScience AG Process for the preparation of thioalkylamine derivatives
CN1960973A (zh) * 2004-03-30 2007-05-09 惠氏公司 作为去甲肾上腺素(ne)与血清素(5－h t)活性和单胺重摄取的调控剂以治疗血管舒缩症状(vms)的1－(1h－吲哚－1－基)－3－(4－甲基哌嗪－1－基)－1－苯基丙烷－2－醇衍生物和相关化合物
US7517899B2 (en) * 2004-03-30 2009-04-14 Wyeth Phenylaminopropanol derivatives and methods of their use
ATE525354T1 (de) 2004-05-03 2011-10-15 Janssen Pharmaceutica Nv Benzofuranderivate als selektive androgenrezeptormodulatoren (sarms)
EP1756109B1 (en) 2004-05-03 2016-07-13 Janssen Pharmaceutica NV Novel indole derivatives as selective androgen receptor modulators (sarms)
US7282507B2 (en) 2004-05-03 2007-10-16 Janssen Pharmaceutica N.V. Indole derivatives as selective androgen receptor modulators (SARMS)
ES2340180T3 (es) * 2004-06-01 2010-05-31 F.Hoffmann-La Roche Ag 3-amino-1-arilpropil-indoles como inhibidores de reabsorcion de monoaminas.
EP1913000B1 (en) * 2005-07-29 2012-01-11 Pfizer Products Inc. Pyrrolo[2,3-d]pyrimidine derivatives; their intermediates and synthesis
GB0526246D0 (en) * 2005-12-22 2006-02-01 Novartis Ag Organic compounds
CN101426778A (zh) * 2006-03-15 2009-05-06 惠氏公司 作为组胺-3拮抗剂的n-经取代-氮杂环基胺
BRPI0709612A2 (pt) 2006-03-15 2011-07-19 Wyeth Corp composto de fórmula i; método para o tratamento de um distúrbio no sistema nervoso central relacionado ou afetado pelo receptor histamina-3 em um paciente que necessita deste tratamento; método para a inibição do receptor h3; composição farmacêutica; e processo para a preparação de um composto de fórmula i
ES2452343T3 (es) 2006-09-29 2014-04-01 Glaxosmithkline Llc Compuestos de indol sustituidos
JP4884570B2 (ja) * 2008-08-20 2012-02-29 ファイザー・インク ピロロ［２，３−ｄ］ピリミジン化合物
WO2010118287A1 (en) * 2009-04-10 2010-10-14 Radius Health, Inc. Selective androgen receptor modulators
JP5629324B2 (ja) * 2009-10-15 2014-11-19 ファイザー・インク ピロロ［２，３−ｄ］ピリミジン化合物
WO2011075334A1 (en) * 2009-12-18 2011-06-23 Pfizer Inc. Pyrrolo[2,3-d]pyrimidine compounds
BR112013000414A2 (pt) 2010-07-07 2016-05-17 Univ Texas compostos proneurogênicos
EP2665707B1 (en) * 2011-01-20 2017-01-18 Merck Sharp & Dohme Corp. Mineralocorticoid receptor antagonists
DK2796460T3 (en) * 2011-12-21 2018-08-27 Jiangsu Hengrui Medicine Co SEXUAL PYRROL HETEROARYL RING DERIVATIVES, METHOD OF PREPARATION AND MEDICAL APPLICATIONS THEREOF
AU2013291721B2 (en) * 2012-07-17 2016-02-25 Glaxosmithkline Intellectual Property (No.2) Limited Indolecarbonitriles as selective androgen receptor modulators
WO2015110958A1 (en) * 2014-01-21 2015-07-30 Glaxosmithkline Intellectual Property (No.2) Limited Crystalline forms of (r)-1 -(1-(methylsulfonyl)propan-2-yl)-4-(trifluoromethyl)indoline-5-carbonitrile

Also Published As

Publication number Publication date
IL236448A0 (en) 2015-02-26
US10710963B2 (en) 2020-07-14
HUE036238T2 (hu) 2018-06-28
CR20150008A (es) 2015-03-09
CN104619693B (zh) 2019-08-13
PH12015500104B1 (en) 2015-03-02
DK2875013T3 (en) 2018-01-22
US10196353B2 (en) 2019-02-05
US9533948B2 (en) 2017-01-03
EP2875013A1 (en) 2015-05-27
UY34911A (es) 2014-02-28
EA026371B1 (ru) 2017-03-31
CO7240378A2 (es) 2015-04-17
NZ703129A (en) 2017-06-30
TW201416349A (zh) 2014-05-01
JO3384B1 (ar) 2019-03-13
BR112015000940B1 (pt) 2022-05-17
MY198512A (en) 2023-09-01
CN104619693A (zh) 2015-05-13
IN2014KN02993A (es) 2015-05-08
ME02996B (me) 2018-10-20
BR112015000940A2 (pt) 2017-06-27
EA201492237A1 (ru) 2015-06-30
RS56810B1 (sr) 2018-04-30
PL2875013T3 (pl) 2018-06-29
SI2875013T1 (en) 2018-03-30
DOP2015000004A (es) 2015-03-15
CA2879104C (en) 2020-08-25
US20200270210A1 (en) 2020-08-27
LT2875013T (lt) 2018-02-26
JP2015522603A (ja) 2015-08-06
CA2879104A1 (en) 2014-01-23
HRP20180061T1 (hr) 2018-02-23
IL236448A (en) 2016-10-31
US20140024694A1 (en) 2014-01-23
MX349943B (es) 2017-08-21
PE20150371A1 (es) 2015-03-27
US20150080449A1 (en) 2015-03-19
PT2875013T (pt) 2018-02-28
MX2015000825A (es) 2015-07-17
MY173845A (en) 2020-02-24
WO2014013309A1 (en) 2014-01-23
ES2657912T3 (es) 2018-03-07
US11299457B2 (en) 2022-04-12
HK1208867A1 (en) 2016-03-18
US20170073309A1 (en) 2017-03-16
KR20150032333A (ko) 2015-03-25
AU2013291721B2 (en) 2016-02-25
US8957104B2 (en) 2015-02-17
EP2875013B1 (en) 2017-11-29
KR102127939B1 (ko) 2020-06-29
ZA201500096B (en) 2017-07-26
AU2013291721A1 (en) 2015-02-26
US20190127326A1 (en) 2019-05-02
JP6106746B2 (ja) 2017-04-05
TWI574946B (zh) 2017-03-21
PH12015500104A1 (en) 2015-03-02
CL2015000119A1 (es) 2015-04-24
SG11201408493WA (en) 2015-02-27
EA026371B8 (ru) 2017-06-30
CY1120064T1 (el) 2018-12-12

Similar Documents

Publication Publication Date Title
AR091770A1 (es) Indolcarbonitrilos moduladores selectivos de receptores androgenicos
AR101815A1 (es) Compuestos y composiciones como inhibidores de quinasa
AR102977A1 (es) Inhibidores de erk
AR093767A1 (es) Compuestos de bis(fluoroalquil)-1,4-benzodiazepinona y profarmacos de estos
AR090474A1 (es) Compuestos de tetrahidropirrolotiazina
AR098912A1 (es) Inhibidores de syk
AR099177A1 (es) Determinadas (2s)-n-[(1s)-1-ciano-2-feniletil]-1,4-oxazepan-2-carboxamidas como inhibidores de dipeptidil peptidasa 1
AR093818A1 (es) Compuesto de 1-(bencil sustituido)piperazina sustituida
AR091271A1 (es) Pirrolopirimidona y pirrolopiridona, inhibidores de tanquirasa
EA201591632A1 (ru) Цитотоксические и антимитотические соединения и способы их применения
AR095423A1 (es) 2-azabiciclos sustituidos y su uso como moduladores del receptor de orexina
AR097866A1 (es) Derivados de 4-azaindol
AR095421A1 (es) Moduladores de p2x7
AR091519A1 (es) Inhibidores pirrolopirazona de tanquirasa
AR094959A1 (es) Compuestos de imidazo piridina
AR096837A1 (es) Heterociclos tricíclicos como inhibidores de proteínas bet
RS54730B1 (sr) Inhibitori beta sekretaze
AR098908A1 (es) Compuesto de (6s,9as)-n-bencil-6-[(4-hidroxifenil)metil]-4,7-dioxo-8-({6-[3-(piperazin-1-il)azetidin-1-il]piridin-2-il}metil)-2-(prop-2-en-1-il)-octahidro-1h-pirazino[2,1-c][1,2,4]triazina-1-carboxamida
AR105549A1 (es) Compuestos de 1-alquil-6-oxo-1,6-dihidropiridin-3-ilo y usos de los mismos
AR094812A1 (es) Derivado de piridina monocíclico como inhibidor del fgfr
AR098522A1 (es) Compuesto de triazolo-piridina
AR093937A1 (es) Compuestos quimicos
AR089771A1 (es) Derivados de bencil sulfonamida utiles como inhibidores de mogat-2
AR099646A1 (es) Fotoestabilizantes de aminas impedidas
AR080703A1 (es) Derivados de 3-(heteroaril-amino)-1,2,3,4-tetrahidro-9h-carbazol, moduladores de receptores de prostaglandina d2, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de trastornos alergicos o inmunitarios tales como asma.

Legal Events

Date Code Title Description
FG Grant, registration